```
┌─────────────────────────────────┐
│  Total number of men recruited  │
│  from Swedish AMORIS database    │
│                                  │
│  N= 391672                       │
└─────────────────────────────────┘
                │
                ▼
┌─────────────────────────────────┐        ┌──────────────────────────────┐
│  Men with prostate cancer        │        │ Excluded                     │
│                                  │───────▶│                              │
│  N= 23136                        │        │ - 5995 men without any       │
│                                  │        │   information on PSA levels, │
└─────────────────────────────────┘        │   Gleason grade, and TNM     │
                │                           │   stage                      │
                ▼                           │ - 2847 whose glucose, total  │
┌─────────────────────────────────┐        │   cholesterol and triglycerides│
│  Men included in analyses        │        │   measurements were not      │
│                                  │        │   taken on the same day      │
│  N= 14294                        │        └──────────────────────────────┘
└─────────────────────────────────┘
```

PSA (µg/l)	Gleason grade	T-stage	Risk categories
<4 (N=1164)	Low (N= 6942)	T1-T2 (N= 11087)	**Localised**
4-9 (N=6126)	Intermediate (N= 4789)	T3-T4 (N= 2815)	- Low risk (N= 4472)
10-20 (N=3219)	High (N= 2320)	Missing (N= 392)	- Intermediate risk (N= 4032)
>20 (N=3351)	Missing (N= 243)		- High risk = (N= 3258),
Missing (N= 434)			**Regional/distant metastatic** (N= 2187)
			Missing (N= 345)

Figure S1: Schematic representation of study population